Skip to main content
WHANIN PHARM CO.,LTD logo

WHANIN PHARM CO.,LTD — Investor Relations & Filings

Ticker · 016580 ISIN · KR7016580003 KO Manufacturing
Open in API
Filings indexed 179 across all filing types
Latest filing 2020-08-28 Interim / Quarterly Rep…
Country KR South Korea
Listing KO 016580

About WHANIN PHARM CO.,LTD

https://www.whanin.com/?lang=eng

WHANIN PHARM CO.,LTD. is a pharmaceutical company that develops, manufactures, and sells a range of therapeutic products. The company specializes in medications for the Central Nervous System (CNS), with a particular focus on neuropsychiatric treatments such as anti-psychotics and CNS stimulants. In addition to its core CNS portfolio, Whanin Pharm's product line includes pharmaceuticals for the cardiovascular and gastrointestinal systems, antibiotics, and vitamin supplements. The company also provides development and manufacturing services for finished drug formulations.

Recent filings

Filing Released Lang Actions
반기보고서 (2020.06)
Interim / Quarterly Report Classification · 100% confidence The document is a '반기보고서' (Semi-annual Report) for Whan In Pharm Co., Ltd. for the period 2020.01.01 to 2020.06.30. It contains comprehensive financial statements, management discussion and analysis, and operational details, which aligns with the definition of an Interim/Quarterly Report (IR). H1 2020
2020-08-28 Korean
연결재무제표기준영업(잠정)실적(공정공시)
Earnings Release Classification · 100% confidence The document is a 'Preliminary Earnings Release' (영업(잠정)실적) for Hwanin Pharmaceutical. It provides key financial highlights (revenue, operating profit, net income) for the second quarter of 2020. It is a standard initial announcement of financial results, which fits the definition of an Earnings Release (ER). H1 2020
2020-08-10 Korean
주식등의대량보유상황보고서(약식)
Major Shareholding Notification Classification · 100% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding), which is a standard regulatory filing in South Korea used by institutional investors (in this case, Shinyoung Asset Management) to disclose changes in their shareholding percentage in a specific company (Hwanin Pharmaceutical). This falls under the category of Major Shareholding Notification.
2020-08-03 Korean
주식등의대량보유상황보고서(약식)
Major Shareholding Notification Classification · 100% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding), which is a standard regulatory filing in South Korea (often referred to as the 5% rule report). It details the change in share ownership by International Value Advisers, LLC in Hwanin Pharmaceutical Co., Ltd. This document type is specifically used to notify the market of significant changes in shareholding levels, which falls under the 'Major Shareholding Notification' category.
2020-07-24 Korean
주식등의대량보유상황보고서(약식)
Major Shareholding Notification Classification · 100% confidence The document is a 'Report on Large Shareholding' (주식등의 대량보유상황보고서) filed in South Korea. It details the change in share ownership by International Value Advisers, LLC in Hwanin Pharmaceutical Co., Ltd. This type of filing is specifically used to notify the market when a shareholder's stake crosses a significant threshold (typically 5%). According to the provided definitions, this falls under 'Major Shareholding Notification'.
2020-06-24 Korean
주식등의대량보유상황보고서(약식)
Major Shareholding Notification Classification · 100% confidence The document is a 'Report of Large Shareholding' (주식등의 대량보유상황보고서), which is a regulatory filing required when an entity's shareholding in a listed company crosses certain thresholds (typically 5%). The document details the shareholding changes of ShinYoung Asset Management in Hwanin Pharmaceutical. This falls under the 'Major Shareholding Notification' category.
2020-06-08 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.